Rapid Cell-Free Preparation of Circular Vector DNA for pegRNA Expression in Prime Editing
Summary
The expression of prime editing guide RNA (pegRNA) is crucial for effective CRISPR-Cas9 prime genome editing, traditionally facilitated by DNA plasmids, which require a time-consuming process of bacterial cloning, validation, and purification. The Circular Vector (CV) protocol represents an efficient, fully synthetic, cell-free method that bypasses these traditional steps, allowing for the preparation of pegRNA expression vectors within 3 h.
Keywords
The expression of prime editing guide RNA (pegRNA) is crucial for effective CRISPR-Cas9 prime genome editing, traditionally facilitated by DNA plasmids, which require a time-consuming process of bacterial cloning, validation, and purification. The Circular Vector (CV) protocol represents an efficient, fully synthetic, cell-free method that bypasses these traditional steps, allowing for the preparation of pegRNA expression vectors within 3 h. This approach involves circularizing and purifying linear double-stranded DNA (dsDNA) templates containing a promoter with pegRNA elements into compact, bacterial-backbone-free vectors. These CVs offer significant advantages: absence of a bacterial backbone, absence of endotoxins, and no contamination by bacterial nucleic acids, making them a superior choice for transfection in cell culture experiments, where they have shown performance equal to or better than that of traditional plasmids. The CV protocol not only speeds up the preparation process but also reduces costs and complexity, making it an ideal tool for rapid and efficient pegRNA expression in research settings.
Abstract from PubMed (PMID 43015541). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Orthogonal ensemble and single-particle characterisation of antisense oligonucleotide lipid nanoparticles
Discover nanoLipid nanoparticle-based mRNA delivery system for cancer management
Molecular cancersiRNA-mediated mismatch repair disruption synergizes with oxaliplatin to restore immune surveillance in microsatellite-stable colorectal cancer
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
